Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6CNS 5Other hematologic neoplasm 3Gastrointestinal 3Myeloid 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Rhabdomyosarcoma 1Recurrence 1Neuroblastoma 1Medulloblastoma 1Hepatoblastoma 1Glioma 1Astrocytoma 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × sonidegib × Sarcoma × Clear all
NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Novartis

Phase 1/2 Completed
76 enrolled 18 charts
CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡